Role of oral chemotherapy in colorectal cancer

Research output: Contribution to journalArticle

Abstract

Despite the long clinical history of 5-FU in gastrointestinal cancer, the development of oral agents has been a productive endeavor, and oral fluoropyrimidine agents are likely to play an important role in the management of colorectal cancer. Results of recent trials in advanced/metastatic colorectal cancer have shown equivalence of response rates, time to disease progression, and median survival and reduced rates of neutropenia and stomatitis with oral capecitabine (Xeloda) or UFT/leucovorin compared with standard fluorouracil (5-FU)/leucovorin regimens. Evaluation of these oral agents in adjuvant therapy, in combination chemotherapy, and in combination with radiation therapy is ongoing.

Original languageEnglish (US)
Pages (from-to)243-245
Number of pages3
JournalOncology
Volume14
Issue number11 A
StatePublished - 2000

Fingerprint

Fluorouracil
Colorectal Neoplasms
Leucovorin
Drug Therapy
Stomatitis
Gastrointestinal Neoplasms
Mouth Neoplasms
Combination Drug Therapy
Neutropenia
Disease Progression
Radiotherapy
History
Capecitabine
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Role of oral chemotherapy in colorectal cancer. / Donehower, Ross C.

In: Oncology, Vol. 14, No. 11 A, 2000, p. 243-245.

Research output: Contribution to journalArticle

Donehower, Ross C. / Role of oral chemotherapy in colorectal cancer. In: Oncology. 2000 ; Vol. 14, No. 11 A. pp. 243-245.
@article{b03a4cc79708439bb57bfde276fe31e7,
title = "Role of oral chemotherapy in colorectal cancer",
abstract = "Despite the long clinical history of 5-FU in gastrointestinal cancer, the development of oral agents has been a productive endeavor, and oral fluoropyrimidine agents are likely to play an important role in the management of colorectal cancer. Results of recent trials in advanced/metastatic colorectal cancer have shown equivalence of response rates, time to disease progression, and median survival and reduced rates of neutropenia and stomatitis with oral capecitabine (Xeloda) or UFT/leucovorin compared with standard fluorouracil (5-FU)/leucovorin regimens. Evaluation of these oral agents in adjuvant therapy, in combination chemotherapy, and in combination with radiation therapy is ongoing.",
author = "Donehower, {Ross C}",
year = "2000",
language = "English (US)",
volume = "14",
pages = "243--245",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "11 A",

}

TY - JOUR

T1 - Role of oral chemotherapy in colorectal cancer

AU - Donehower, Ross C

PY - 2000

Y1 - 2000

N2 - Despite the long clinical history of 5-FU in gastrointestinal cancer, the development of oral agents has been a productive endeavor, and oral fluoropyrimidine agents are likely to play an important role in the management of colorectal cancer. Results of recent trials in advanced/metastatic colorectal cancer have shown equivalence of response rates, time to disease progression, and median survival and reduced rates of neutropenia and stomatitis with oral capecitabine (Xeloda) or UFT/leucovorin compared with standard fluorouracil (5-FU)/leucovorin regimens. Evaluation of these oral agents in adjuvant therapy, in combination chemotherapy, and in combination with radiation therapy is ongoing.

AB - Despite the long clinical history of 5-FU in gastrointestinal cancer, the development of oral agents has been a productive endeavor, and oral fluoropyrimidine agents are likely to play an important role in the management of colorectal cancer. Results of recent trials in advanced/metastatic colorectal cancer have shown equivalence of response rates, time to disease progression, and median survival and reduced rates of neutropenia and stomatitis with oral capecitabine (Xeloda) or UFT/leucovorin compared with standard fluorouracil (5-FU)/leucovorin regimens. Evaluation of these oral agents in adjuvant therapy, in combination chemotherapy, and in combination with radiation therapy is ongoing.

UR - http://www.scopus.com/inward/record.url?scp=0034327687&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034327687&partnerID=8YFLogxK

M3 - Article

C2 - 11195416

AN - SCOPUS:0034327687

VL - 14

SP - 243

EP - 245

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 11 A

ER -